Abstract
Purpose
To report the effect and visual improvement of internal limiting membrane (ILM) peeling, and epiretinal mem-brane (ERM) peeling in symptomatic ERM with pseudolamellar macular hole.
Methods
This study included 27 eyes in 26 consecutive patients with ERM including pseudolamellar macular hole that un-derwent vitrectomy, ERM peeling, intravitreal gas tamponade, and maintained a face-down position for 7 days. ILM peel-ing was performed only in 13 eyes of 13 patients. The patients were divided into 2 groups: eyes with or without ILM peeling (14 eyes and 13 eyes, respectively) and the follow-up period was 12 months or more in all cases. The postoperative ana-tomic results based on optical coherence tomography (OCT) and improvement of best corrected visual acuity (BCVA) were retrospectively compared between the 2 groups.
Results
Anatomic closure after surgery was achieved in 11 eyes (78.6%) in the ILM without peeling group and in 12 eyes (92.3%) in the ILM with peeling group ( p = 0.596). The BCVA improved from 0.41 ± 0.31 (log MAR) to 0.33 ± 0.21 in the ILM without peeling group ( p = 0.479) and from 0.46 ± 0.41 (log MAR) to 0.28 ± 0.25 in the ILM with peeling group ( p = 0.001).
References
1. Gass JD. Lamellar macular hole: a complication of cystoid macular edema after cataract extraction: a clinicopathologic case report. Trans Am Ophthalmol Soc. 1975; 73:231–50.
2. Allen AW Jr, Gass JD. Contraction of a perifoveal epiretinal mem-brane simulating a macular hole. Am J Ophthalmol. 1976; 82:684–91.
3. Gass JDM. Vitreofoveal separation and lamellar hole formation Steroscopic atlas of macular disease: diagnosis and treatment. 4th ed. St Louis: CV Mosby;p. p 926–7.
4. Takahashi H, Kishi S. Tomographic features of a lamellar macular hole formation and a lamellar hole that progressed to a full-thick-ness macular hole. Am J Ophthalmol. 2000; 130:677–9.
5. Haouchine B, Massin P, Tadayoni R, et al. Diagnosis of macular pseudoholes and lamellar macular holes by optical coherence tomography. Am J Ophthalmol. 2004; 138:732–9.
6. Witkin AJ, Ko TH, Fujimoto JG, et al. Redefining lamellar holes and the vitreomacular interface: an ultrahigh-resolution optical co-herence tomography study. Ophthalmology. 2006; 113:388–97.
7. Chen JC, Lee LR. Clinical spectrum of lamellar macular defects in-cluding pseudoholes and pseudocysts defined by optical coherence tomography. Br J Ophthalmol. 2008; 92:1342–6.
8. Androudi S, Stangos A, Brazitikos PD. Lamellar macular holes: to-mographic features and surgical outcome. Am J Ophthalmol. 2009; 148:420–6.
9. Kinoshita T, Kovacs KD, Wagley S, Arroyo JG. Morphologic dif-ferences in epiretinal membranes on ocular coherence tomography as a predictive factor for surgical outcome. Retina. 2011; 31:1692–8.
10. Kelly NE, Wendel RT. Vitreous surgery for idiopathic macular holes. Results of a pilot study. Arch Ophthalmol. 1991; 109:654–9.
11. Haouchine B, Massin P, Gaudric A. Foveal pseudocyst as the first step in macular hole formation: a prospective study by optical co-herence tomography. Ophthalmology. 2001; 108:15–22.
12. Michalewski J, Michalewska Z, Dzię gielewski K, et al. Evolution from macular pseudohole to lamellar macular hole - spectral do-main OCT study. Graefes Arch Clin Exp Ophthalmol. 2011; 249:175–8.
13. Fine BS. Limiting membranes of the sensory retina and pigment epithelium. An electron microscopic study. Arch Ophthalmol. 1961; 66:847–60.
14. de Bustros S, Thompson JT, Michels RG, et al. Vitrectomy for idio-pathic epiretinal membranes causing macular pucker. Br J Ophthalmol. 1988; 72:692–5.
15. de Bustros S, Rice TA, Michels RG, et al. Vitrectomy for macular pucker. Use after treatment of retinal tears or retinal detachment. Arch Ophthalmol. 1988; 106:758–60.
16. Mittleman D, Green WR, Michels RG, de la Cruz Z. Clinicopathologic correlation of an eye after surgical removal of an epiretinal membrane. Retina. 1989; 9:143–7.
17. Witkin AJ, Castro LC, Reichel E, et al. Anatomic and visual out-comes of vitrectomy for lamellar macular holes. Ophthalmic Surg Lasers Imaging. 2010; 41:418–24.
18. Michalewska Z, Michalewski J, Odrobina D, et al. Surgical treat-ment of lamellar macular holes. Graefes Arch Clin Exp Ophthalmol. 2010; 248:1395–400.
19. Garretson BR, Pollack JS, Ruby AJ, et al. Vitrectomy for a sympto-matic lamellar macular hole. Ophthalmology. 2008; 115:884–6.
20. Haritoglou C, Gass CA, Schaumberger M, et al. Macular changes after peeling of the internal limiting membrane in macular hole surgery. Am J Ophthalmol. 2001; 132:363–8.
21. Uemoto R, Yamamoto S, Takeuchi S. Epimacular proliferative re-sponse following internal limiting membrane peeling for idio-pathic macular holes. Graefes Arch Clin Exp Ophthalmol. 2004; 242:177–80.
22. Simddy WE, Feuer W, Cordahi G. Internal limiting membrane peel-ing in macular hole Surgery. Ophthalmology. 2001; 108:1471–8.
23. Engelbrecht NE, Freeman J, Sternberg Jr P, et al. Retinal pigment epithelial changes after macular hole surgery with indocyanine green-assisted internal limiting membrane peeling. Am J Ophthalmol. 2002; 133:89–94.
24. Gale JS, Proulx AA, Gonder JR, et al. Comparison of the in vitro toxicity of green to that of trypan blue in human retinal pigment ep-ithelium cell cultures. Am J Ophthalmol. 2004; 138:64–9.
25. Umeura A, Kanda S, Sakamoto Y, Kita H. Visual field defects after uneventful vitrectomy for epiretinal membrane with indocyanine green-assisted internal limiting membrane peeling. Am J Ophthalmol. 2003; 136:252–7.
26. Kwok AK, Lai TY, Yuen KS, et al. Macular hole surgery with or without indocyanine green stained internal limiting peeling. Clin Exp Ophthalmol. 2003; 31:470–5.
27. Park UC, Park KH, Yu YS, Chung H. Comparision of indocyanine green and triamcinolone acetonide for internal limiting membrane peeling in macular hole. J Korean Ophthalmol Soc. 2005; 46:1995–2003.
Table 1.
Table 2.
Group 1* | Group 2† | Total | |
---|---|---|---|
Sex (M : F) | 4 : 10 (14) | 2 : 11 (13) | 6 : 21 (27) |
Age (years) | 66.7 (53-74) | 63.7 (46-81) | 65.3 |
Phakic : Pseudophakic | 10 : 4 | 10 : 3 | 20 : 7 |
Combined cataract surgery | 10 (71.4%) | 10 (76.9%) | 20 (74.1%) |
Follow-up (months) | 17.9 (12-32) | 16.9 (12-36) | 17.4 |
Table 3.
Group 1* | Group 2† | p-value | |
---|---|---|---|
Preoperative BCVA (log MAR) | 0.41 ± 0.31 | 0.46 ± 0.41 | 0.882§ |
Final BCVA (log MAR) | 0.33 ± 0.21 | 0.28 ± 0.25 | 0.082§ |
p-value | 0.479‡ | 0.001‡ |
Table 4.
Same or <2 snellen lines improvement | >2 snellen lines improvement | >2 snellen lines worsening | Total | |
---|---|---|---|---|
Group 1* | 5 (35.7%) | 5 (35.7%) | 4 (28.6%) | 14 |
Group 2† | 4 (30.8%) | 9 (69.2%) | 0 (0%) | 13 |
p‐ value | 0.074‡ | 27 |
Table 5.
Group 1* | Group 2† | p-value | |
---|---|---|---|
Anatomical success | 11 (14) 78.6% | 12 (13) 92.3% | 0.596‡ |
Functional success | 5 (14) 35.7% | 9 (13) 69.2% | 0.021‡ |